Quantcast

Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference

January 8, 2013

Experts from Cato BioVentures and Cancer Advances are attending Biotech Showcase 2013 and J.P. Morgan 31st Annual Healthcare Conference this week in San Francisco. These two annual events bring together private and public investors and pharmaceutical executives from around the world to meet in one place for two of the healthcare industry’s largest conferences.

Durham, NC (PRWEB) January 07, 2013

Experts from Cato BioVentures and Cancer Advances are attending Biotech Showcase 2013 and J.P. Morgan 31st Annual Healthcare Conference this week in San Francisco. These two annual events bring together private and public investors and pharmaceutical executives from around the world to meet in one place for two of the healthcare industry’s largest conferences.

Attending experts include: Daniel Pharand, C.P.A., C.A., Principal of Cato BioVentures and Chief Financial Officer of Cato Research as well as Chief Executive Officer and Chief Financial Officer of Cancer Advances; Jo Cato, Ph.D., Vice President of Cato BioVentures and Chief Operating Officer of Cato Research; and David Gee, Strategic Business Developer of Cato Research.

These experts, along with other Cato BioVentures and Cancer Advances representatives, will participate in Biotech Showcase 2013, attending one-on-one partnering meetings and the J.P. Morgan conference.

To set up a meeting with Cato BioVentures or Cancer Advances, please call 919-361-2286. For more information, you may visit:

http://www.cato.com/marketing/2013/2013-Biotech_CatoBioVentures.html

About Cato BioVentures:

Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry´s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company´s business plan, then Cato BioVenture´s investment model can make a positive difference in the company´s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit http://www.catobioventures.com.

About Cancer Advances:

Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html

About Cato Research:

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients´ products to market with speed and cost effectiveness. For more information about Cato Research, visit http://www.cato.com.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10292438.htm


Source: prweb



comments powered by Disqus